Biotech

Histogenics (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, announced its financial and operational results for the quarter and year ended December 31, 2017. As quoted in the press release: “We achieved multiple, significant milestones in our global development strategy for NeoCart in …

Histogenics (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, announced its financial and operational results for the quarter and year ended December 31, 2017.

As quoted in the press release:

“We achieved multiple, significant milestones in our global development strategy for NeoCart in 2017, providing a strong foundation for additional value creation in 2018. With the completion of enrollment in the NeoCart Phase 3 clinical trial in the first half of 2017, we are on track to report top-line data from this trial and potentially submit a Biologics License Application for this novel restorative cell therapy in the third quarter of 2018. In parallel we are initiating pre-commercialization activities for the U.S. market in advance of a potential launch of NeoCart in fourth quarter of 2019, and we continue to hear positive anecdotal feedback from our investigators regarding NeoCart patients,” stated Adam Gridley, President and Chief Executive Officer of Histogenics.

Click here to read the full press release.

MARKETS

Markets
TSX20165.43-104.54
TSXV658.96-10.61
DOW33900.19-251.82
S&P 5004262.69-42.51
NASD12895.32-207.23
ASX7105.40+41.10

COMMODITIES

Commodities
Gold1766.04-9.44
Silver19.79-0.34
Copper3.58-0.05
Palladium2144.00-1.00
Platinum930.00-4.00
Oil87.36+0.83
Heating Oil3.52+0.08
Natural Gas9.27-0.06

DOWNLOAD FREE REPORTS

×